Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

The National Comprehensive Cancer Network

McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,046

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Lopez, B. A., Barrios, C. H., Bergh, J. C. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,194

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

O’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Rugo, H. S., Rumble, R. B., Macrae, E. R., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L. J., Fowble, B. F., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 640

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

Miller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 538

Precision Medicine in Cholangiocarcinoma: Past, Present, and Future

Cheng, C.-Y., Chen, C., & Wu, C. (2022) · Life · doi:10.3390/life12060829 · Cited by 19

Targeting micro-environmental pathways by PROTACs as a therapeutic strategy

Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20

Inactivation of Hippo pathway characterizes a poor-prognosis subtype of esophageal cancer

Mai, Z., Yuan, J., Yang, H., Fang, S., Xie, X., Wang, X., Xie, J., Wen, J., & Fu, J. (2022) · JCI Insight · doi:10.1172/jci.insight.155218 · Cited by 18

Computational pathology to improve biomarker testing in breast cancer: how close are we?

Sajjadi, E., Frascarelli, C., Venetis, K., Bonizzi, G., Ivanova, M. D., Vago, G. G., Guerini‐Rocco, E., & Fusco, N. (2023) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000804 · Cited by 19

Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics

Ding, Y. C., Song, H., Adamson, A. W., Schmolze, D. B., Hu, D., Huntsman, S., Steele, L., Patrick, C. S., Tao, S., Hernandez, N., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2510 · Cited by 17

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer

Cataldo, M. L., Placido, P. D., Esposito, D., Formisano, L., Arpino, G., Giuliano, M., Bianco, R., Angelis, C. D., & Veneziani, B. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1108242 · Cited by 19

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Hopcroft, L., Wigmore, E. M., Williamson, S. C., R�os, S., Eberlein, C., Moss, J. I., Urosevic, J., Carnevalli, L. S., Talbot, S., Bradshaw, L., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00571-w · Cited by 19

Frequency of genetic alterations differs in advanced breast cancer between metastatic sites

Grote, I., Poppe, A., Lehmann, U., Christgen, M., Kreipe, H. H., & Bartels, S. (2023) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23199 · Cited by 24

Decoding the functional impact of the cancer genome through protein–protein interactions

Fu, H., Mo, X., & Ivanov, A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00784-6 · Cited by 22

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets

Moreira, A., Masliah‐Planchon, J., Callens, C., Vacher, S., Lecerf, C., Frélaut, M., Borcoman, É., Torossian, N., Ricci, F., Hescot, S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.001 · Cited by 19

Precision medicine for ovarian clear cell carcinoma based on gene alterations

Kuroda, T., & Kohno, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01622-z · Cited by 19

Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer

Bardia, A., Modi, S., Oliveira, M., Cortés, J., Campone, M., Ma, B., Dirix, L., Weise, A. M., Hewes, B., Diaz-Padilla, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1068 · Cited by 20

Clinical and neuroimaging findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future clinical trials

Garde, A., Guibaud, L., Goldenberg, A., Petit, F., Dard, R., Roume, J., Mazereeuw‐Hautier, J., Chassaing, N., Lacombe, D., Morice‐Picard, F., et al. (2021) · Clinical Genetics · doi:10.1111/cge.13918 · Cited by 19

Organismal roles for the PI3Kα and β isoforms: their specificity, redundancy or cooperation is context-dependent.

Arcucci, S., Ramos-Delgado, F., Cayron, C., Therville, N., Gratacap, M., Basset, C., Thibault, B., & Guillermet-Guibert, J. (2021) · Biochemical Journal · doi:10.1042/bcj20210004 · Cited by 15

Oligometastatic Breast Cancer: How to Manage It?

Barberi, V., Pietragalla, A., Franceschini, G., Marazzi, F., Paris, I., Cognetti, F., Masetti, R., Scambia, G., & Fabi, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060532 · Cited by 18

Anticancer potential of novel α,β-unsaturated γ-lactam derivatives targeting the PI3K/AKT signaling pathway

Brindisi, M., Frattaruolo, L., Mancuso, R., Piccionello, A. P., Ziccarelli, I., Catto, M., Nicolotti, O., Altomare, C., Gabriele, B., & Cappello, A. R. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114659 · Cited by 19

Current State of Cell Therapies for Breast Cancer

Gautam, N., Elleson, K. M., Ramamoorthi, G., & Czerniecki, B. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000607 · Cited by 19

The Present and Future of Clinical Management in Metastatic Breast Cancer

Lin, P., & Laliotis, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195891 · Cited by 19

Elacestrant and the Promise of Oral SERDs

Sanchez, K. G., Nangia, J. R., Schiff, R., & Rimawi, M. F. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00841 · Cited by 19

Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes

Hossain, M. T., & Hossain, M. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177432 · Cited by 21

Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions

Ziranu, P., Pretta, A., Saba, G., Spanu, D., Donisi, C., Ferrari, P. A., Cau, F., D’Agata, A. P., Piras, M., Mariani, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157619 · Cited by 19

Patient acceptability of circulating tumour DNA testing in endometrial cancer follow‐up

Relton, A., Collins, A., Guttery, D. S., Gorsia, D. N., McDermott, H. J., & Moss, E. L. (2021) · European Journal of Cancer Care · doi:10.1111/ecc.13429 · Cited by 16

Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

Volckmar, A., Christopoulos, P., Kirchner, M., Allgäuer, M., Neumann, O., Budczies, J., Rempel, E., Horak, P., Glade, J., Goldschmid, H., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.022 · Cited by 18

Large‐scale genomic sequencing reveals adaptive opportunity of targeting mutated‐PI3Kα in early and advanced HER2‐positive breast cancer

Guo, L., Li, X., Yang, Y., Lu, X., Han, X., Lang, G., Chen, L., Shao, Z., & Hu, X. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.589 · Cited by 17

Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors

Thulin, A., Andersson, C., Rönnerman, E. W., Lara, S. D., Chamalidou, C., Schoenfeld, A., Kovács, A., Fagman, H., Enlund, F., & Linderholm, B. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-02903-x · Cited by 18

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer

Welslau, M., Hartkopf, A. D., Müller, V., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., Schütz, F., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9952 · Cited by 18

Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer

Main, S. C., Cescon, D. W., & Bratman, S. V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.37 · Cited by 20

The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?

da Luz, F. A. C., Araújo, B. J., & de Araújo, R. A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103781 · Cited by 18

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience

Alaklabi, S., Roy, A. M., Attwood, K. M., George, A. M., O’Connor, T. L., Early, A., Levine, E. G., & Gandhi, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1012391 · Cited by 18

Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kα selective inhibitors

Wang, Y., Liu, Y., Ge, T., Tang, J., Wang, S., Gao, Z., Chen, J., Xu, J., Gong, P., Zhao, Y., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106211 · Cited by 18

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer

West, M. T., Goodyear, S. M., Hobbs, E. A., Kaempf, A. J., Kartika, T., Ribkoff, J., Chun, B., & Mitri, Z. I. (2023) · The Oncologist · doi:10.1093/oncolo/oyad035 · Cited by 18

Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer

Yang, C., Wang, M., Gong, Y., Deng, M., Li, Q., Li, Q., Wang, J., & Zhou, Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106779 · Cited by 18

Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis

Püsküllüoğlu, M., Rudzińska, A., & Pacholczak‐Madej, R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188991 · Cited by 19

A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer

Shao, H., Zhao, M., Guan, A., Shao, T., Zhou, D., Yu, G., & Tang, W. (2024) · BMC Medicine · doi:10.1186/s12916-023-03238-2 · Cited by 21

Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer

Toska, E. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189097 · Cited by 18

Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer

Blawski, R., Vokshi, B., Guo, X., Kittane, S., Sallaku, M., Chen, W., Gjyzari, M., Cheung, T., Zhang, Y., Simpkins, C. E., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114174 · Cited by 19

CDK4/6 inhibitors: The Devil is in the Detail

Magge, T., Rajendran, S., Brufsky, A., & Foldi, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01540-7 · Cited by 19

PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis

Yamaguchi, J., Isnard, P., Robil, N., de la Grange, P., Hoguin, C., Schmitt, A., Hummel, A., Megret, J., Goudin, N., Luka, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176402 · Cited by 21

Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers

Ibanez, K. R., Huang, T., & Lee, J.-M. (2024) · Cells · doi:10.3390/cells13121064 · Cited by 19

Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44

Malik, N., Nirujogi, R. S., Peltier, J., Macartney, T., Wightman, M., Prescott, A. R., Gourlay, R., Trost, M., Alessi, D. R., & Karapetsas, A. (2019) · Biochemical Journal · doi:10.1042/bcj20190608 · Cited by 18

Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis

Cha, C., Ahn, S. G., Yoo, T.-K. R., Kim, G. M., Bae, S. J., Yoon, C. I., Park, S., Sohn, J., & Jeong, J. (2019) · Breast Care · doi:10.1159/000503847 · Cited by 18

Novel targeted therapies for metastatic breast cancer

Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 18

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

Toomey, S., Carr, A., Mezynski, J., Elamin, Y. Y., Rafee, S., Cremona, M., Morgan, C., Madden, S. F., Jalil, K. I. A., Gately, K. A., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02273-4 · Cited by 17

PDGFRβ plays an essential role in patient vitreous-stimulated contraction of retinal pigment epithelial cells from epiretinal membranes

Yang, Y., Huang, X., Ma, G., Cui, J. Z., Matsubara, J. A., Kazlauskas, A., Zhao, J., Wang, J., & Lei, H. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108116 · Cited by 18

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer

Khoury, K. E., Tan, A. R., Elliott, A., Xiu, J., Gatalica, Z., Heeke, A. L., Isaacs, C. J., Pohlmann, P. R., Schwartzberg, L. S., Simon, M. S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01475 · Cited by 19

Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?

Starzyńska, A., Adamska, P., Sejda, A., Sakowicz‐Burkiewicz, M., Adamski, Ł. J., Marvaso, G., Wychowański, P., & Jereczek‐Fossa, B. A. (2020) · Life · doi:10.3390/life10120325 · Cited by 18

Recent updates in systemic therapy of breast cancer

Arora, S., & Gogia, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_335_20 · Cited by 18

Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology

Choi, H. W., Naskar, M., Seo, H. K., & Lee, H. W. (2021) · Biomedicines · doi:10.3390/biomedicines9111500 · Cited by 18

BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer

Bogani, G., Chiappa, V., Bini, M., Ronzulli, D., Indini, A., Conca, E., & Raspagliesi, F. (2022) · Tumori Journal · doi:10.1177/03008916211073621 · Cited by 18

Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis

Lin, X., Guo, L., Lin, X., Wang, Y., & Zhang, G. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e30 · Cited by 17

Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance

Duta-Ion, S. G., Juganaru, I. R., Hotinceanu, I. A., Dan, A., Burtavel, L. M., Coman, M. C., Focșa, I. O., Zaruha, A.-G., Codreanu, P. C., Bohîlțea, L. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312507 · Cited by 23

Engineered crRNA Drives RPA‐T7‐CRISPR/Cas14a Cascade for Ultrasensitive Detection of ctDNA PIK3CA H1047R

Yu, Y., Jin, M., Yuan, W., Gong, Y., Li, S., Qin, X., Hou, J., Liu, J., Liu, S., Li, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202507126 · Cited by 18

Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older

Kim, M. H., Kim, G. M., Kim, J. H., Kim, J. Y., Park, H. S., Park, S., Cho, Y. U., Park, B., Kim, S. I., & Sohn, J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05505-4 · Cited by 16

Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy

Michmerhuizen, N. L., Owen, J. H. J., Neal, M. E. H., Mann, J. E., Leonard, E., Wang, J., Zhai, J., Jiang, H., McHugh, J. B., Brenner, J. C., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03418-7 · Cited by 17

Multiple mutations within individual oncogenes

Saito, Y., Koya, J., & Kataoka, K. (2020) · Cancer Science · doi:10.1111/cas.14699 · Cited by 17

Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis

Raphael, J., Lefebvre, C., Allan, A. L., Helou, J. A., Boldt, G., Vandenberg, T. A., & Blanchette, P. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00770-6 · Cited by 18

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

Sturgill, E. G., Misch, A., Lachs, R., Jones, C. C., Schlauch, D., Jones, S. F., Shastry, M., Yardley, D. A., Burris, H. A., Spigel, D. R., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00469 · Cited by 17

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer

Migliaccio, I., Paoli, M., Risi, E., Biagioni, C., Biganzoli, L., Benelli, M., & Malorni, L. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00382-5 · Cited by 17

In vitro anticancer effects of alpelisib against PIK3CA‑mutated canine hemangiosarcoma cell lines

Maeda, M., Ochiai, K., Michishita, M., Morimatsu, M., Sakai, H., Kinoshita, N., Sakaue, M., Onozawa, E., Azakami, D., Yamamoto, M., et al. (2022) · Oncology Reports · doi:10.3892/or.2022.8295 · Cited by 17

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Magbanua, M. J. M., Gümüşay, Ö., Kurzrock, R., Veer, L. V. ‘., & Rugo, H. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.802579 · Cited by 18

Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients

Nicosia, L., Figlia, V., Ricottone, N., Cuccia, F., Mazzola, R., Giaj‐Levra, N., Ricchetti, F., Rigo, M., Jafari, F., Magrini, S. M., et al. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10167-6 · Cited by 17

Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib

Mondielli, G., Mougel, G., Darriet, F., Roche, C., Querdray, A., Lisbonis, C., Appay, R., Dufour, H., Chinot, O. L., Graillon, T., et al. (2022) · Cancers · doi:10.3390/cancers14184448 · Cited by 17

Development of PI3Kα inhibitors for tumor therapy

Jia, W., Luo, S., Guo, H. W., & Kong, D. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2132293 · Cited by 20

Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma

Rudloff, U. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2134346 · Cited by 17

Evaluating everolimus for the treatment of breast cancer

Moreau-Bachelard, C., Robert, M., Gourmelon, C., Bourbouloux, E., Patsouris, A., Frenel, J., & Campone, M. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2214677 · Cited by 17

PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma

Choi, S., Kim, H., Heo, Y. J., Kang, S. Y., Ahn, S., Lee, J., & Kim, K. (2023) · The Journal of Pathology · doi:10.1002/path.6134 · Cited by 17

Genomic Characterization of Aggressive Breast Cancer in Younger Women

Franco, I. “., Alshalalfa, M., Hernandez, A. E., Mahal, B. A. V., Nguyen, T., Wang, L., Punglia, R. S., Swami, N. S., & Goel, N. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14080-4 · Cited by 19

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer

Pegram, M. D., Pietras, R. J., Dang, C. T., Murthy, R. K., Bachelot, T., Janni, W., Sharma, P., Hamilton, E. P., & Saura, C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231187201 · Cited by 20

Insights into the mechanisms and structure of breakage-fusion-bridge cycles in cervical cancer using long-read sequencing

Rodriguez, I., Rossi, N. M., Keşküş, A. G., Xie, Y., Ahmad, T., Bryant, A., Lou, H., Paredes, J. M. G., Milano, R., Rao, N., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.01.002 · Cited by 15

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer

Rodon, J. A., Demanse, D., Rugo, H. S., Burris, H. A., Simó, R., Farooki, A., Wellons, M., André, F., Hu, H., Vuina, D., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01773-1 · Cited by 17

Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials

Apostolidou, K., Zografos, E., Papatheodoridi, A. M., Fiste, O., Dimopoulos, M. A., & Zagouri, F. (2024) · The Breast · doi:10.1016/j.breast.2024.103729 · Cited by 19

Cryo-EM structures reveal two allosteric inhibition modes of PI3KαH1047R involving a re-shaping of the activation loop.

Huang, X., Wang, K., Han, J., Chen, X.-M., Wang, Z., Wu, T.-L., Yu, B., Zhao, F., Wang, X., Li, H., et al. (2024) · Structure · doi:10.1016/j.str.2024.03.007 · Cited by 14

Advances in Personalized Oncology

Mechahougui, H., Gutmans, J., Colarusso, G., Gouasmi, R., & Friedlaender, A. (2024) · Cancers · doi:10.3390/cancers16162862 · Cited by 19

Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment

Guo, Z., Dong, R. W., Wu, Y., Dong, S., & Alahari, S. K. (2025) · Oncogene · doi:10.1038/s41388-025-03378-0 · Cited by 18

MRI-based radiogenomics analysis for predicting genetic alterations in oncogenic signalling pathways in invasive breast carcinoma

Lin, P., LIU, W.-H., Li, X., Wan, D., Qin, H., Li, Q., Chen, G., He, Y., & Yang, H. (2020) · Clinical Radiology · doi:10.1016/j.crad.2020.02.011 · Cited by 17

Copanlisib in the treatment of non-Hodgkin lymphoma

Narkhede, M. S., & Cheson, B. D. (2020) · Future Oncology · doi:10.2217/fon-2020-0195 · Cited by 17

Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer

Philipovskiy, A. V., Dwivedi, A. K., Gamez, R., McCallum, R. W., Mukherjee, D., Nahleh, Z. A., Aguilera, R. J., & Gaur, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238262 · Cited by 17

PIK3CA mutations matter for cancer in dogs

Kim, J. H. (2020) · Research in Veterinary Science · doi:10.1016/j.rvsc.2020.09.001 · Cited by 17

Discovery and SAR of Novel Disubstituted Quinazolines as Dual PI3Kalpha/mTOR Inhibitors Targeting Breast Cancer

Al‐Ashmawy, A. A. K., Elokely, K. M., Perez-Leal, O., Rico, M. C., Gordon, J. C., Mateo, G. D., Omar, A. M., Abou-Gharbia, M. A., & Childers, W. E. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00289 · Cited by 17

Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer

Vidula, N., Niemierko, A., Malvarosa, G., Yuen, M., Lennerz, J. K., Iafrate, A. J., Wander, S. A., Spring, L. M., Juric, D., Isakoff, S. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3444 · Cited by 17

Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer

Mouabbi, J. A., Osborne, C. K., Schiff, R., & Rimawi, M. F. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06383-5 · Cited by 19

Omics analyses of a somatic Trp53 R245W/+ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling

Yu, X., Zhang, Y., Xiong, S., McDaniel, J. M., Sun, C., Chau, G. P., Gencel‐Augusto, J., Chachad, D., Morrissey, R. L., Rao, X., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210618119 · Cited by 16

Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review

Fiste, O., Liontos, M., Koutsoukos, K., Terpos, E., Dimopoulos, M. A., & Zagouri, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1175 · Cited by 16

Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care

Moore, H., Goncalves, M. D., Johnston, A. M., Mayer, E. L., Rugo, H. S., Gradishar, W. J., Zylla, D. M., & Bergenstal, R. M. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.09.017 · Cited by 15

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations

Bielo, L. B., Rocco, E. G., Trapani, D., Zagami, P., Salimbeni, B. T., Esposito, A., Belli, C., Crimini, E., Venetis, K., Munzone, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103731 · Cited by 17

Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies

Arora, K. S., Suehnholz, S. P., Zhang, H., Ostrovnaya, I., Kundra, R., Nandakumar, S., Nissan, M. H., Brannon, A. R., Bandlamudi, C., Ladanyi, M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5794 · Cited by 16

Prioritizing Parkinson’s disease risk genes in genome-wide association loci

Lange, L. M., Cerquera‐Cleves, C., Schipper, M., Panagiotaropoulou, G., Braun, A., Kraft, J., Awasthi, S., Bell, N., Posthuma, D., Ripke, S., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00933-0 · Cited by 18

Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer

Jhaveri, K. L., Iyengar, N. M., Turner, N. C., Rugo, H. S., O’Shaughnessy, J., Barrios, C. H., Curigliano, G., André, F., Im, S., Goncalves, M. D., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.105936 · Cited by 19

Metastatic breast cancer patient perceptions of somatic tumor genomic testing

Adams, E., Asad, S., Reinbolt, R. E., Collier, K. A., Abdel‐Rasoul, M., Gillespie, S., Chen, J. L., Cherian, M. A., Noonan, A. M., Sardesai, S. D., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06905-2 · Cited by 16

PIK3CA Mutation Assessment in HR+/HER2− Metastatic Breast Cancer: Overview for Oncology Clinical Practice

Criscitiello, C., Marra, A., & Curigliano, G. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2010005 · Cited by 16

Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones

Malebari, A. M., Morales, G. D., Twamley, B., Fayne, D., Khan, M. F., McLoughlin, E. C., O’Boyle, N. M., Zisterer, D. M., & Meegan, M. J. (2022) · Pharmaceuticals · doi:10.3390/ph15091044 · Cited by 16

Computational Design of Phosphatidylinositol 3-Kinase Inhibitors

Rani, I., Goyal, A., & Sharma, M. (2022) · Assay and Drug Development Technologies · doi:10.1089/adt.2022.057 · Cited by 16

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative

Ascione, L., Zagami, P., Nicolò, E., Crimini, E., Curigliano, G., & Criscitiello, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111793 · Cited by 16

Immune subtype identification and multi-layer perceptron classifier construction for breast cancer

Yang, X., Zheng, Y., Xing, X., Sui, X., Jia, W., & Pan, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943874 · Cited by 17

Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K α inhibitors

Chen, R., Wang, Z., Sima, L., Hu, C., Luo, B., Wang, J., Guo, B., Mao, S., Zhou, Z., Peng, J.-G., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2155638 · Cited by 16

Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications

Zhao, Z., Li, X., Wang, F., Xu, Y., Liu, S., Han, Q., Yang, Z., Huang, W., Yin, Z., Liu, Q., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5871 · Cited by 15

N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer

der Maur, P. A., Trefny, M. P., Baumann, Z., Vulin, M., Correia, A. L., Diepenbruck, M., Kramer, N., Volkmann, K., Preca, B., Ramos, P. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101002 · Cited by 17

Colorectal cancer: Review of signaling pathways and associated therapeutic strategies

Leiphrakpam, P. D., Rajappa, S. J., Krishnan, M., Batra, R., Murthy, S. S., & Are, C. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27295 · Cited by 17

Network pharmacology, molecular docking and experimental verification help unravel chelerythrine's potential mechanism in the treatment of gastric cancer

Kang, K., Han-bing, J., Bing-lin, C., & Shu-jun, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17393 · Cited by 16

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

Yu, Y., Xiao, Z., Lei, C., Ma, C., Ding, L., Tang, Q., He, Y., Chen, Y., Chang, X., Zhu, Y.-J., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11243-0 · Cited by 16

Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer

Leenhardt, F., Alexandre, M., & Jacot, W. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873952 · Cited by 21

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Narayan, P., Prowell, T. M., Gao, J. J., Fernandes, L. L., Li, E., Jiang, X., Qiu, J., Fan, J., Song, P., Yu, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3652 · Cited by 167

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Roufai, D. B., Gonçalvès, A., Rouge, T. D. L. M., Akla, S., Blonz, C., Grenier, J., Gligorov, J., Saghatchian, M., Bailleux, C., Simon, H., et al. (2023) · Oncogene · doi:10.1038/s41388-022-02585-3 · Cited by 22

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice

Filonenko, D., Ibragimova, T., Ивановна, П. Н., Belogurova, A. V., Khatkova, E. I., Arutyunyan, E. A., Volkova, E., & Zhukova, L. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-20-75-82 · Cited by 3

A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer

Bertho, M., Patsouris, A., Augereau, P., Robert, M., Frenel, J., Blonz, C., & Campone, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1844662 · Cited by 11